




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : A61B 5/00</p>	<p>A1</p>	<p>(11) International Publication Number: WO 95/26676</p> <p>(43) International Publication Date: 12 October 1995 (12.10.95)</p>
---	------------------	---

<p>(21) International Application Number: PCT/US95/04050</p> <p>(22) International Filing Date: 31 March 1995 (31.03.95)</p> <p>(30) Priority Data: 08/221,911 1 April 1994 (01.04.94) US</p> <p>(71) Applicant (for all designated States except US): NELLCOR INCORPORATED [US/US]; 4280 Hacienda Drive, Pleasanton, CA 94588 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): CASCIANI, James, R. [US/US]; 7985 Pumpkin Court, Cupertino, CA 95014 (US). MANNHEIMER, Paul, D. [US/US]; 2619 Read Avenue, Belmont, CA 94002 (US). NIERLICH, Steve, L. [US/US]; 264 Cherrywood Avenue, San Leandro, CA 94577 (US). RUSKEWICZ, Stephen, J. [US/US]; 183 Ardmore Road, Kensington, CA 94707 (US).</p> <p>(74) Agents: HAUGHEY, Paul, C. et al.; Townsend and Townsend Hourie and Crew, 20th floor, One Market Plaza, Steuart Street Tower, San Francisco, CA 94105 (US).</p>	<p>(81) Designated States: AT, AU, BR, CA, CH, CN, CZ, DE, DK, ES, FI, GB, JP, KR, LU, NL, NO, NZ, PT, SE, SG, SK, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published With international search report.</p>
---	--

(54) Title: PULSE OXIMETER AND SENSOR OPTIMIZED FOR LOW SATURATION



(57) Abstract

A pulse oximeter sensor (410) with a light source optimized for low oxygen saturation ranges and for maximizing the immunity to perturbation induced artifact. Preferably, a red (112) and an infrared light source (114) are used, with the red light source (112) having a mean wavelength between 700-790 nm. The infrared light source (114) can have a mean wavelength as in prior art devices used on patients with high saturation. The sensor of the present invention is further optimized by arranging the spacing between the light emitter (112, 114) and light detectors (116) to minimize the sensitivity to perturbation induced artifact. The present invention optimizes the chosen wavelengths to achieve a closer matching of the absorption and scattering coefficient products for the red and IR light sources. This optimization gives robust readings in the presence of perturbation artifacts including force variations, tissue variations and variations in the oxygen saturation itself.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgystan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

PULSE OXIMETER AND SENSOR OPTIMIZED FOR LOW SATURATION

5

This is a continuation-in-part of U.S. application serial number 08/221,911, filed April 1, 1994.

BACKGROUND OF THE INVENTION

10

Pulse oximetry is used to continuously monitor the arterial blood oxygen saturation of adults, pediatrics and neonates in the operating room, recovery room, intensive care units, and increasingly on the general floor. A need exists for pulse oximetry in the delivery room for monitoring the oxygen status of a fetus during labor and delivery, and for monitoring the oxygen status of cardiac patients.

15

Pulse oximetry has traditionally been used on patient populations where arterial blood oxygen saturation is typically greater than 90%, *i.e.*, more than 90% of the functional hemoglobin in the arterial blood is oxyhemoglobin and less than 10% is reduced hemoglobin. Oxygen saturation in this patient population rarely drops below 70%. When it does drop to such a low value, an unhealthy clinical condition is indicated, and intervention is generally called for. In this situation, a high degree of accuracy in the estimate of saturation is not clinically relevant, as much as is the trend over time.

20

25

Conventional two wavelength pulse oximeters emit light from two Light Emitting Diodes (LEDs) into a pulsatile tissue bed and collect the transmitted light with a photodiode positioned on an opposite surface (transmission pulse oximetry), or an adjacent surface (reflectance pulse oximetry). The LEDs and photodetector are housed in a reusable or disposable sensor which connects to the pulse oximeter electronics and display unit. The "pulse" in pulse oximetry comes from the time varying amount of arterial blood in the tissue during the cardiac cycle, and the processed signals from the photodetector create the familiar

30

35

plethysmographic waveform due to the cycling light attenuation. For estimating oxygen saturation, at least one of the two LEDs' primary wavelength must be chosen at some point in the electromagnetic spectrum where the absorption of oxyhemoglobin (HbO₂) differs from the absorption of reduced hemoglobin (Hb). The second of the two LEDs' wavelength must be at a different point in the spectrum where, additionally, the absorption differences between Hb and HbO₂ are different from those at the first wavelength. Commercial pulse oximeters utilize one wavelength in the near red part of the visible spectrum near 660 nanometers (nm), and one in the near infrared part of the spectrum in the range of 880 nm - 940 nm (See Fig. 1). As used herein, "red" wavelengths or "red" spectrum will refer to the 600-800 nm portion of the electromagnetic spectrum; "near red", the 600-700 nm portion; "far red", the 700-800 nm portion; and "infrared" or "near infrared", the 800-1000 nm portion.

Photocurrents generated within the photodetector are detected and processed for measuring the modulation ratio of the red to infrared signals. This modulation ratio has been observed to correlate well to arterial oxygen saturation as shown in Fig. 2. Pulse oximeters and pulse oximetry sensors are empirically calibrated by measuring the modulation ratio over a range of in vivo measured arterial oxygen saturations (SaO₂) on a set of patients, healthy volunteers or animals. The observed correlation is used in an inverse manner to estimate saturation (SpO₂) based on the real-time measured value of modulation ratios. (As used herein, SaO₂ refers to the in vivo measured functional saturation, while SpO₂ is the estimated functional saturation using pulse oximetry.)

The choice of emitter wavelengths used in conventional pulse oximeters is based on several factors including, but not limited to, optimum signal transmission through blood perfused tissues, sensitivity to changes in arterial blood oxygen saturation, and the intensity and availability of commercial LEDs at the desired wavelengths. Traditionally, one of the two wavelengths is chosen from a region of the absorption spectra (Fig. 1) where the extinction

coefficient of HbO₂ is *markedly* different from Hb. The region near 660 nm is where the ratio of light absorption due to reduced hemoglobin to that of oxygenated hemoglobin is greatest. High intensity LEDs in the 660 nm region are also readily available. The IR wavelength is typically chosen near 805 nm (the isosbestic point) for numerical convenience, or in the 880-940 nm spectrum where additional sensitivity can be obtained because of the inverse absorption relationship of Hb and HbO₂. Unfortunately, pulse oximeters which use LED wavelengths paired from the 660 nm band and 900 nm bands all show diminished accuracy at low oxygen saturations.

SUMMARY OF THE INVENTION

According to the invention, more accurate estimates of low arterial oxygen saturation using pulse oximetry are achieved by optimizing a wavelength spectrum of first and second light sources so that the saturation estimates at low saturation values are improved while the saturation estimates at high saturation values are minimally adversely affected as compared to using conventional first and second wavelength spectrums. It has been discovered that calculations at low saturation can be significantly improved if the anticipated or predicted rates of absorption and scattering of the first wavelength spectrum is brought closer to, optimally equal to, the anticipated or predicted rates of absorption and scattering of the second wavelength spectrum than otherwise exists when conventional wavelength spectrum pairs are chosen, such as when conventionally using a first wavelength centered near 660 nm and a second wavelength centered anywhere in the range of 880 nm - 940 nm.

The present invention solves a long felt need for a pulse oximeter sensor and system which provides more accurate estimates of arterial oxygen saturation at low oxygen saturations, i.e. saturations equal to or less than 80%, 75%, 70%, 65%, or 60%, than has heretofore existed in the prior art. The sensor and system is particularly useful for estimating arterial saturation of a living fetus during labor where the saturation range of principal importance and

interest is generally between 15% and 65%, and is particularly useful for estimating arterial saturation of living cardiac patients who experience significant shunting of venous blood into their arteries in their hearts and hence whose saturation range of principle importance and interest is roughly between 50% and 80%. By contrast, a typical healthy human has a saturation greater than 90%. The invention has utility whenever the saturation range of interest of a living subject, either human or animal, is low.

10 In addition to providing better estimates of arterial oxygen saturation at low saturations, the sensor, monitor, and system of the invention further provide better and more accurate oxygen saturation estimates when perturbation induced artifacts exist and are associated with
15 the subject being monitored.

When the rates of absorption and scattering by the tissue being probed by the first and second wavelength spectrums are brought closer together for the saturation values of particular interest, improved correspondence and matching of the tissue actually being probed by the first and second wavelengths is achieved, thus drastically reducing errors introduced due to perturbation induced artifacts. For example, when light of one wavelength is absorbed at a rate significantly higher than that of the other wavelength, the
20 light of the other wavelength penetrates significantly further into the tissue. When the tissue being probed is particularly in-homogenous, this difference in penetrations can have a significant adverse impact on the accuracy of the arterial oxygen saturation estimate.

30 Perturbation induced artifacts include, but are not limited to, any artifact that has a measurable impact on the relative optical properties of the medium being probed. Perturbation induced artifacts include but are not limited to the following:

35 (1) variations in the tissue composition being probed by the sensor from subject to subject, i.e., variations in the relative amounts of fat, bone, brain, skin, muscle, arteries, veins, etc.;

(2) variations in the hemoglobin concentration in the tissue being probed, for example caused by vasal dilations or vasal constrictions, and any other physical cause which affects blood perfusion in the tissue being probed; and

5 (3) variations in the amount of force applied between the sensor and the tissue being probed, thus affecting the amount of blood present in the nearby tissue.

In one embodiment, the present invention provides a fetal pulse oximeter sensor with a light source optimized for
10 the fetal oxygen saturation range and for maximizing the immunity to perturbation induced artifact. Preferably, a far red and an infrared light source are used, with the far red light source having a mean wavelength between 700-790 nm. The infrared light source can have a mean wavelength as in prior
15 art devices used on patients with high saturation, i.e., between 800-1000 nm. As used herein, "high saturation" shall mean an arterial oxygen saturation greater than 70%, preferably greater than 75%, alternatively greater than 80%, optionally greater than 90%.

20 The fetal sensor of the present invention is further optimized by arranging the spacing between the location the emitted light enters the tissue and the location the detected light exits the tissue to minimize the sensitivity to perturbation induced artifact.

25 According to a preferred embodiment, electrooptic transducers (e.g., LEDs and photodetectors) are located adjacent to the tissue where the light enters and exits the tissue. According to an alternate embodiment, the optoelectric transducers are located remote from the tissue,
30 for example in the oximeter monitor, and optical fibers interconnect the transducers and the tissue with the tissue being illuminated from an end of a fiber, and light scattered by the tissue being collected by an end of a fiber. Multiple fibers or fiber bundles are preferred.

35 The present invention recognizes that the typical oxygen saturation value for a fetus is in the range of 5-65%, commonly 15-65%, compared to the 90% and above for a typical

patient with normal (high) saturation. In addition, a fetal sensor is subject to increased perturbation induced artifact. Another unique factor in fetal oximetry is that the sensor is typically inserted through the vagina and the precise location where it lands is not known in advance.

The present invention recognizes all of these features unique to fetal oximetry or oximetry for low saturation patients and provides a sensor which optimizes the immunity to perturbation induced artifacts. This optimization is done with a trade-off on the sensitivity to changes in saturation value. This trade-off results in a more reliable calculation that is not obvious to those who practice the prior art methods which attempt to maximize the sensitivity to changes in the saturation value. The improvement in performance that results from these optimizations are applicable to both reflectance and transmission pulse oximetry. An example of a fetal transmission pulse oximetry configuration usable with the present invention is described in U.S. Patent Application No. 07/752,168, assigned to the assignee of the present invention, the disclosure of which is incorporated herein by reference. An example of a non-fetal transmission pulse oximetry configuration usable with the present invention is described in U.S. Patent No. 4,830,014, assigned to the assignee of the present invention, the disclosure of which is incorporated herein by reference.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a chart of the absorption characteristics of oxyhemoglobin (HbO_2) and reduced hemoglobin (Hb) versus wavelength showing prior art near red and infrared LED wavelengths;

Fig. 2 is a graph of red/IR modulation ratio versus oxygen saturation;

Fig. 3 is a diagram illustrating light penetration through different layers of tissue at different distances;

Fig. 4A is a chart of the variation in extinction and scattering coefficients over a range of wavelengths for different saturation values;

Fig. 4B is a table of the values of Fig. 4A;

Fig. 5 is a diagram illustrating the placing of a sensor on a fetus;

5 Fig. 6 is a graph illustrating the spectrum of an LED according to the present invention;

Figs. 7-18 are graphs showing experimental modeling of the modulation ratio and saturation error as a function of saturation for different red and infrared wavelength combinations;

10 Figs. 19-23 are charts illustrating saturation and the error due to applied force for different combinations of emitter wavelength and emitter-detector spacing from experiments done on sheep;

15 Figs. 24 and 25 are diagrams illustrating the construction of a sensor according to the present invention;

Figs. 26A-B are diagrams of a single package, dual emitter package used in the present invention; and

Fig. 27 is a block diagram of a pulse oximeter according to the present invention.

20

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

An understanding of the design of the fetal sensor according to the present invention requires an understanding of the environment in which the sensor will operate. Fig. 3 illustrates the layers of tissue in a typical fetus location where a sensor may be applied. Typically, there would be a first layer of skin 12, perhaps followed by a layer of fat 14, a layer of muscle 16, and a layer of bone 18. This is a simplified view for illustration purposes only. The contours and layers can vary at different locations. For instance, bone would be closer to the surface on the forehead, as opposed to closer muscle on the neck. Such variations in sites can produce the first type of perturbation artifact mentioned in the summary--artifact due to variations in tissue composition.

25
30
35

The general paths of light from an emitter 20 to a photodetector 22 are illustrated by arrows 24 and 26. Arrow 24 shows light which passes almost directly from emitter 20 to

detector 22, basically shunted from one to the other, passing through very little blood perfused tissue. Arrow 26, on the other hand, illustrates the deeper penetration of another path of the light. The depth of penetration is affected by the wavelength of the light and the saturation. At low saturation, infrared light penetrates deeper than near red, for instance. The deeper penetration can result in an undesirable variation between the infrared and red signals, since the IR signal will pass through more different layers.

Also illustrated in Fig. 3 is the effect of using an emitter 28 which is spaced on the tissue at a greater distance from a detector 30 than the first pair 20, 22 described. As can be seen, this greater separation results in the penetration of a larger amount of tissue, as indicated by arrows 32 and 34. Thus, the greater spacing increases the depth of penetration, although it will reduce the intensity of the signal received at the detector due to more attenuation from more of the light being absorbed in the tissue and the greater light propagation distances involved.

The second type of perturbation mentioned in the summary is variations in the concentration of blood in the tissue from patient to patient or over time. A lower concentration results in less absorption, increasing the penetration depth. The inventors estimate that the mean penetration depth of photons in a medium is related to the product of the absorption and scattering coefficients, and this estimate is consistent with the findings of Weiss et al., *Statistics of Penetration Depth of Photons Re-emitted from Irradiated Tissue*, Journal of Modern Optics, 1989, vol. 36, No. 3, 349-359, 354, the disclosure of which is incorporated herein by reference.

Absorption of light in tissue in the visible and near infrared region of the electromagnetic spectrum is dominated by the absorption characteristics of hemoglobin. Absorption coefficients of hemoglobin can be found in the literature, for example Zijlstra, et al., "Absorption spectra of human fetal and adult oxyhemoglobin, de-oxyhemoglobin, carboxyhemoglobin and methemoglobin", Clinical Chemistry,

37/9, 1633-1638, 1991 (incorporated herein by reference). Measured scattering coefficients of tissue are influenced by the methodology of measurement and the model used to fit the data, although there is general agreement in the relative sensitivity to wavelength regardless of method. Tissue scattering coefficients used by the inventors are based on diffusion theory, and are taken from Schmitt, "Simple photon diffusion analysis of the effects of multiple scattering on pulse oximetry", IEEE Transactions on Biomedical Engineering, Vol. 38, No. 12, December 1991, the disclosure of which is incorporated herein by reference.

Fig. 4A is a graph showing the product of the absorption and scattering coefficients for 0%, 40%, 85% and 100% saturations for wavelengths between 600 nm and 1,000 nm. For 85-100% tissue oxygen saturation, good balance or correlation exists between the product of the absorption and scattering coefficients of conventionally chosen wavelength pairs (i.e., 660 nm and 892 nm), as illustrated by points A and B on curve 101.

For low tissue oxygen saturation, points C and D on curve 102 graphically indicate that there is a very significant mismatch between the product of the absorption and scattering coefficients of the 660 nm near red and 892 nm infrared light, with the near red light being more strongly absorbed and scattered. This very significant absorption and scattering mismatch results in very different tissue being probed by the near red and infrared light which significantly degrades the accuracy of the arterial oxygen saturation calculation. In addition, when a large range of low arterial oxygen saturations need to be accurately calculated, as when monitoring a fetus during labor where the range of arterial oxygen saturations can extend between 15% and 65%, it is evident from Fig. 4A that not only does a significant mismatch between the rates of absorption and scattering of the near red and infrared light exist, but that the amount of mismatch will vary significantly as arterial oxygen saturation varies, thus causing a differential inaccuracy of oxygen saturation estimates which varies with the arterial saturation.

On the other hand, points D and E on curve 102 in Fig. 4A illustrate advantages of a preferred embodiment of the invention of choosing first and second wavelengths, i.e., 732 nm and 892 nm, which have absorption and scattering characteristics which are more closely balanced as compared to the prior art pairing of 660 nm and 892 nm for 40% tissue oxygen saturation. As can be appreciated, since the 732 nm extinction and scattering coefficients more nearly match the 892 nm extinction and scattering coefficients, improved overlap of the tissue being probed by the two wavelengths of light result. In addition, 732 nm results in a smaller variation of the extinction and scattering coefficients as a function of oxygen saturation as compared to 660 nm, thus resulting in better and more accurate oxygen saturation estimates over a wider range of saturations. The tissue oxygen saturation values shown in Fig. 4A are closely correlated to arterial oxygen saturation values. In general, a given value of tissue oxygen saturation corresponds to a higher value of arterial oxygen saturation. For example, the inventors estimate that 85% tissue oxygen saturation corresponds to roughly 100% arterial oxygen saturation.

A preferred embodiment of the invention is to optimize the wavelengths used for a sensor to estimate fetal arterial oxygen saturation during labor where the saturation of interest is below 70%, a typical range of interest being between 15% and 65%. Attempting to match or balance the rates of absorption and scattering of the two wavelengths in a fetal sensor is particularly useful since the amount of perturbation induced artifacts are so severe in number and magnitude. For example, for a surface reflection sensor, it is difficult to know a priori where on the fetus the sensor will be located. For example, sometimes it will be on the head, other times the cheek. Hence, the tissue composition varies from application to application. In addition, the force by which the sensor is applied will vary during labor thus introducing still additional perturbation induced artifacts.

Another preferred embodiment of the invention is to use the sensor of the invention for cardiac patients whose

range of saturation, where accuracy in calculations is important, is from 50% to 80%.

Fig. 5 illustrates the placement of a sensor 410 on a fetus 412. The sensor is connected by a cable 414 to an external pulse oximeter monitor. As can be seen, sensor 410 is wedged between a uterine wall 416 and the fetus 412. In this instance, the sensor is on the side of the fetus' forehead. This wedging of the sensor applies a force to the skin immediately below the sensor, which reduces the amount of blood in the local tissue. This reduces the amount of blood the light signal will pass through, thus increasing the difficulty of obtaining an accurate blood oxygenation reading.

In choosing an optimum LED wavelength, it must be kept in mind that LEDs have a spectral width, and are not a single narrowband wavelength device like a laser. Fig. 6 illustrates the spectral spread of one preferred wavelength for a sensor according to the present invention, showing the far red wavelength at 735 nm as being the peak wavelength. However, arrow 510 indicates a distribution of wavelengths which can be approximately 25 nm wide at which the intensity level is approximately 50% of that of the peak wavelength. In addition, when manufacturing LEDs, it is difficult to tightly control the mean wavelength. Thus, a purchaser specifying a particular wavelength, such as a 735 nm wavelength in an embodiment of the present invention, will expect to receive LEDs whose actual mean wavelength can vary by 10, 20 or more nanometers from the specified value. A narrow range is typically achieved by testing and sorting.

Fig. 27 is a block diagram of one embodiment of a pulse oximeter implementing the present invention. Light from light source 210 passes into patient tissue 212, and is scattered and detected by photodetector 214. A sensor 200 containing the light source and photodetector may also contain an encoder 216 which provides signals indicative of the wavelength of light source 210 to allow the oximeter to select appropriate calibration coefficients for calculating oxygen saturation. Encoder 216 may, for instance, be a resistor.

Sensor 200 is connected to a pulse oximeter 220. The oximeter includes a microprocessor 222 connected to an internal bus 224. Also connected to the bus is a RAM memory 226 and a display 228. A time processing unit (TPU) 230
5 provides timing control signals to light drive circuitry 232 which controls when light source 210 is illuminated, and if multiple light sources are used, the multiplexed timing for the different light sources. TPU 230 also controls the gating-in of signals from photodetector 214 through an
10 amplifier 233 and a switching circuit 234. These signals are sampled at the proper time, depending upon which of multiple light sources is illuminated, if multiple light sources are used. The received signal is passed through an amplifier 236, a low pass filter 238, and an analog-to-digital converter 240.
15 The digital data is then stored in a queued serial module (QSM) 242, for later downloading to RAM 26 as QSM 242 fills up. In one embodiment, there may be multiple parallel paths of separate amplifier filter and A/D converters for multiple light wavelengths or spectrums received.

20 A detector and decoder module 242 determines the wavelength of the light source from encoder 216. One embodiment of circuitry for accomplishing this is shown in commonly assigned U.S. Patent No. 4,770,179, the disclosure of which is hereby incorporated by reference.

25 Based on the value of the received signals corresponding to the light received by photodetector 214, microprocessor 222 will calculate the oxygen saturation using well-known algorithms. These algorithms require coefficients, which may be empirically determined, corresponding to, for
30 example, the wavelengths of light used. These are stored in a ROM 246. The particular set of coefficients chosen for any pair of wavelength spectrums is determined by the value indicated by encoder 216 corresponding to a particular light source in a particular sensor 200. In one embodiment,
35 multiple resistor values may be assigned to select different sets of coefficients. In another embodiment, the same resistors are used to select from among the coefficients appropriate for an infrared source paired with either a near

red source or far red source. The selection between whether the near red or far red set will be chosen can be selected with a control input from control inputs 254. Control inputs 254 may be, for instance, a switch on the pulse oximeter, a
5 keyboard, or a port providing instructions from a remote host computer.

The inventors of the present invention use both modeling and prototypes to achieve the optimized sensor set forth herein. Several theoretical models exist for describing the scattering of light within tissue. The models used by the
10 inventors assume isotropic scattering within a homogeneous tissue bed. Even though this is a simplification of the true nature of light scattering in tissue (tissue is inhomogeneous and light is scattered primarily in the forward direction),
15 these models are useful for predicting behaviors of pulse oximetry, and the sensitivity to many design parameters.

Utilizing such a model, different choices of LED wavelengths were explored. Tissue characteristics were numerically defined and the basis (calibration) correlation
20 between SaO_2 and modulation ratio was calculated for each wavelength pair considered. Change in physiological condition was simulated by revising one or more of the numerically defined physical parameters. SpO_2 was recalculated from the resulting modulation ratio, and the saturation region where
25 errors were minimized was noted. For arterial saturations above 80% the conventional wavelength choice of 660 nm paired with 890 nm results in optimum performance, while for arterial saturations below 70%, 735 nm band emitters paired with 890 nm gives improved stability.

Figs. 7 through 18 show the predicted errors due to changing the *tissue blood volume* to one fourth the basis value for a variety of red and IR LED wavelength pairs. The A
30 figures (such as 7A) show the modulation ratio vs. SaO_2 . The B figures (7B) show the saturation error vs. SaO_2 . This
35 perturbation simulates the effects of blood volume variations within the patient population, anemia, ischemia, or localized exsanguination of blood in the tissue.

Sensitivity of the calibration to a change in tissue blood concentration is shown for several pairings of red and IR wavelengths. In each case, the LED has no secondary emission, and the perturbation is in going from a nominal 2% blood concentration in the tissue to 0.5%.

Figure Table

	IR LED		
red LED	805 nm	890 nm	940 nm
660 nm	7	8	9
700 nm		10	
730 nm	11	12	13
760 nm	14	15	16
790 nm		17	18

Figs. 7-9 show the type of performance found in conventional pulse oximeters. Figs. 10-18 show shifting of the optimum performance region from saturations above 80% to lower saturations when the red LED wavelength is chosen in the 700 nm - 790 nm region of the spectrum. Light scattering is minimally affected by changes in oxygenation, but light absorption is significantly affected as reduced hemoglobin in the tissue changes to oxyhemoglobin or vice-versa. Pulse oximetry's optimum performance region occurs when there is a balance of the two channels' scattering and absorption properties within blood perfused tissue. Balance occurs when there is a good overlap of the volumes of tissue probed by the two channels, requiring that the penetration depth of light at the two wavelengths be matched. At the higher saturations, this optimum balance occurs with the pairing of wavelengths with a red emitter in the 660 nm band, while at the lower saturations the balance improves with the use of a red emitter in the 730 nm band. The variation of the IR LED from 805 to 940 nm does not produce a significant difference in performance.

When using an LED pair near 730 nm and 890 nm for pulse oximetry, the sensitivity of modulation ratio to changes in oxygen saturation (*i.e.*, the slope of the curve in, for example, Fig. 1) is reduced relative to the use of 660 nm and 890 nm, but the measurement becomes more robust to changes in the tissue characteristics other than oxygen saturation. Noise in the measurement of modulation ratio due to factors such as instrument electronics noise, digitization, or ambient light interference, become more important but can generally be accounted for with good instrument design and appropriate signal processing. The bias and deviations due to tissue optical properties, however, become less significant with the proper choice of emitter wavelengths when they are chosen based on the saturation region of primary interest.

The inventors conducted empirical tests on sheep using prototype sensors. The empirical observations support the use of 735 nm band red LEDs in the design of a pulse oximeter that is more robust to perturbation induced artifacts at the lower saturation region. Reflectance pulse oximetry sensors were fabricated using conventional 660 nm - 890 nm LED pairs, and with 735 nm - 890 nm pairs.

Figs. 19-23 show that measurements were taken at a range of oxygen saturation values indicated along the X axis from approximately 100% oxygen saturation to less than 10%. The plots show the calculated saturation (SpO_2) for each actual saturation (SaO_2) value. The actual saturation value is determined by simultaneously drawing blood samples from an arterial catheter placed in the left femoral artery. SaO_2 is measured on a laboratory co-oximeter (Instrument Labs IL 282 or Radiometer OSM-3). This is the value used on the X axis in these figures.

As can be seen, the diagonal line in Figs. 19, 20, and 22 indicates the desired result where the calculated value is equal to the actual value as measured with the catheter. The tests illustrated in Figs. 19, 20, and 22 were done with a nominal force of approximately 50 grams applied to the sensor holding it against the skin.

Using the 660 nm sensor with center-to-center emitter/detector spacing of 14 mm at the tissue, Fig. 19 shows that sensor calibration is very sensitive to the type of tissue probed. The calibration on the head and neck are very different.

Using the 735 nm sensor with a 5.8 mm center-to-center emitter/detector spacing at the tissue, the bias between the head and neck is greatly reduced as illustrated by Fig. 20. There is, however, still substantial sensitivity to surface exsanguination. This is apparent in Fig. 21 which illustrates the effect of a perturbation induced artifact (sensor applied force).

Fig. 22 shows the location insensitivity of a 735 nm sensor with a 14 mm center-to-center emitter/detector spacing. Fig. 23 shows that this sensor is also insensitive to force applied to the sensor (perturbation induced artifact).

It was experimentally confirmed that increasing the emitter/detector center-to-center spacing from 5.8 mm for 735nm/890nm LED wavelengths decreased the sensitivity to perturbation induced artifacts, with good performance being achieved by an emitter/detector separation equal to or greater than 10 mm.

Both the modeling and the actual experiments illustrate an improvement in reliability of a saturation measurement achieved by optimizing the red wavelength to be within 700-790 nm range. In addition, reduction of the saturation error reading in the presence of force artifact is achieved by increasing the spacing of the emitters from the detector.

The force applied to the sensor causes exsanguination of the surface tissue, further magnifying the remaining disparities due to the inhomogeneity of the tissue, or causing shunting of light between the emitter and detector, thus causing errors in the saturation calculation. These are compensated for by wider emitter/detector spacing, which results in the light from the red and infrared LEDs penetrating deeper into the tissue, thus increasing the

likelihood of their going through, on the average, the same combination of tissue structures, as illustrated in Fig. 3.

Fig. 24 is a top view of a sensor according to one embodiment of the present invention. The sensor face 110 supports a far red LED 112 and an infrared LED 114. These are spaced by a distance of 14 mm center-to-center from a detector 116. Preferably, the centers of the far red and infrared LEDs are no more than 0.5 mm apart. The sensor face is connected by a cable 118 to a connector 120 for connection to the pulse oximeter monitor. Fig. 25 shows a side view of the sensor of Fig. 24, illustrating the fulcrum portion 122 of the sensor and sensor back 132. When placed in utero, the uterus will apply a force to the sensor back 132 and deform the fulcrum 122. As can be seen, this technique results in a force being applied to the sensor resulting in good sensor-fetus contact but possibly resulting in local exsanguination of the tissue. It should be noted that any sensor embodiment will have possible local exsanguination.

The modeling and empirical tests show that the nature of the correlation between modulation ratio and saturation in pulse oximetry is related to tissue optical properties, and that the sensitivity to varying perturbation induced artifacts can be affected by choice of emitter wavelengths. For high oxygen saturations, the choice of 660 nm and 890 nm band emitters is well suited for stable pulse oximetry calculations, while 700-790 nm and 890 nm band emitters perform better at low saturations. Other wavelength combinations may be chosen from elsewhere in the visible and near infrared portion of the spectrum by following an analysis similar to the one described here. Currently, however, overall instrument design considerations (e.g., electronic signal-to-noise and potential shunting of light with narrowly spaced components in a reflectance probe) favor the use of the wavelengths discussed. By using the analysis described, other improvements to pulse oximetry are possible. Figs. 19-23 illustrate the results of these tests for several prototype sensors.

Figs. 26A and 26B are front and side views of a single package containing emitters 112 and 114 of Figs. 24 and 25. Both emitters are encapsulated in a single semiconductor package, to make the package more compact to provide the miniaturization which is advantageous for a fetal sensor application. In the embodiment of Fig. 26A, emitter die 112 is mounted via a conductive epoxy 130 to a substrate 132. Substrate 132 takes the form of a metal plating, an exterior portion 134 of which forms the outside lead to the package. Emitter 114 is mounted on top of metal substrate 136, an exterior 138 of which forms the second lead.

The electrical connection to emitter 114 is provided through lead 138 on one side up through the conductive epoxy, and through the other side via a wire bond 140, which connects to the other lead 134. Similarly, lead 134 connects through conductive epoxy 130 to the second emitter 112, with the other side of emitter 112 connected via a wire bond 142 to lead 138. Accordingly, as can be seen, applying a voltage with a first polarity to the two leads 134 and 138 will turn on one of the emitters, and turn off the other, while reversing the polarity will reverse which emitter is turned on and which emitter is turned off. Both of the emitters and their corresponding substrates are encapsulated in a package 144 which may, for instance, be plastic.

Fig. 26B is a side view showing the encapsulated package 144 from the side, and illustrating the emitting light 146 from emitters 112, 114. The structure of Figs. 26A-26B is compact and usable for a fetal application. Preferably, the distance between the centers of the two emitter dies 112 and 114 is less than 2mm. This way the package's wiring allows the package to have two leads, as opposed to four leads which would be required by using two separate emitter packages.

As an alternative to using a far red and an infrared LED, other methods for producing selected light spectrums of two different wavelengths can be used. For example, lasers could be used rather than LEDs. Alternately, a white light or other light source could be used, with the wavelength being optimized at the detector. This could be done by using

appropriate filters in front of either the light source or the detector, or by using a wavelength sensitive detector. If filters are used, they could be placed in front of alternate detectors or emitters, or filters could be alternately
5 activated in front of a single emitter or detector.

A pulse oximeter for use over a broad saturation range can utilize multiple wavelength pairs (e.g., both 660 nm and 730 nm band emitters coupled with a 900 nm emitter), with the appropriate emitter pair chosen for use in the calculation
10 of SpO₂ based on the estimated value of the oxygen saturation.

Such a pulse oximeter could be implemented with two or more red LEDs, or alternately could be implemented with a single light source and multiple filters, or multiple wavelength sensitive detectors. Different red wavelength
15 spectrums could be utilized, based on the saturation of the patient.

As will be understood by those with skill in the art, the present invention can be embodied in other specific forms without departing from the essential characteristics
20 thereof. The wavelength could be varied while still optimizing in accordance with the present invention. Also, light pipes, light fibers, multiple filters, or multiple detectors could be used in accordance with the concepts of the present invention. Different sensors than the fulcrum
25 structure as set forth in Fig. 25 could be used, such as a bladder structure for inflating and holding the sensor against the fetus. Accordingly, reference should be made to the appended claims for defining the scope of the invention.

30

35

WHAT IS CLAIMED IS:

- 1 1. A method for measuring blood oxygen saturation,
2 comprising the steps of:
3 providing a sensor and a pulse oximeter;
4 selecting a light source and a light detector;
5 optimizing a wavelength spectrum of light
6 received by said light detector from said light source
7 for an oxygen saturation reading less than 80 percent;
8 placing said sensor on a patient; and
9 determining said blood oxygen saturation using
10 said sensor and said pulse oximeter.
- 1 2. The method of claim 1, wherein said optimizing
2 step is for an oxygen saturation of a fetus.
- 1 3. The method of claim 2, including optimizing said
2 wavelength spectrum for an oxygen saturation reading less than
3 65 percent.
- 1 4. The method of claim 2, including optimizing said
2 wavelength spectrum for an oxygen saturation reading greater
3 than 15%.
- 1 5. The method of claim 2 further comprising the
2 step of:
3 placing a detector on said sensor;
4 optimizing a spacing of said light source from
5 said detector to reduce the sensitivity of said sensor to
6 perturbation induced artifact; and
7 measuring the intensity of light from said
8 light source at said detector using light scattered
9 through said fetus.
- 1 6. The method of claim 4 wherein a spacing between
2 where said light is injected into said tissue and collected
3 from said tissue is at least 10 mm.

1 7. The method of claim 1 wherein said received
2 light comprises a red spectrum and an infrared spectrum, each
3 of said red and infrared spectrums having an extinction and a
4 scattering coefficient associated with blood perfused tissue,
5 said optimizing step comprising choosing wavelength spectrums
6 within said red and infrared spectrums whose product of their
7 respective extinction and scattering coefficients form first
8 and second values, a ratio between said first and second
9 values being between 0.5 and 2 for a majority of the oxygen
10 saturation reading range of 0 to 65 percent.

1 8. The method of claim 2 wherein said received
2 light comprises a red spectrum and an infrared spectrum, said
3 optimizing step comprising using a first spectrum within said
4 infrared spectrum in a range useful for a patient having high
5 saturation, and optimizing the red spectrum to a second
6 spectrum for a fetus.

1 9. The method of claim 8 wherein the mean
2 wavelength of said second spectrum is between 700 and 790
3 nanometers.

1 10. The method of claim 8 wherein said second
2 spectrum includes 735 nanometers at an intensity of at least
3 50% of the intensity of any other wavelengths in said second
4 spectrum.

1 11. The method of claim 2 wherein said optimizing
2 step increases a depth of penetration of said light in a fetus
3 compared to an optimum penetration depth for a patient having
4 high saturation.

1 12. The method of claim 1 wherein said optimizing
2 step reduces the sensitivity of said determining step to
3 artifact.

1 13. The method of claim 1 wherein said optimizing
2 step includes selecting said light source to have a desired
3 wavelength spectrum.

1 14. The method of claim 1 wherein said optimizing
2 step includes selecting said light detector which detects a
3 limited spectrum of light.

1 15. The method of claim 1 wherein said optimizing
2 step includes filtering said light source to pass a desired
3 wavelength spectrum.

1 16. The method of claim 1 further comprising the
2 step of alternately optimizing said wavelength spectrum of
3 light received by said light detector from said light source
4 for an oxygen saturation reading greater than 80 percent.

1 17. A method for measuring blood oxygen saturation
2 in a fetus, comprising the steps of:
3 providing a sensor and a pulse oximeter;
4 selecting a light source and a light detector;
5 detecting light at said detector comprising red
6 and infrared spectrums;
7 selecting the infrared spectrum so as to have a
8 wavelength spectrum useful for measuring oxygen
9 saturation in a patient with high saturation;
10 optimizing a wavelength spectrum of said red
11 spectrum to a mean wavelength between 700 and 790
12 nanometers for an oxygen saturation reading between 15
13 and 65 percent, said optimizing increasing an immunity of
14 a measurement of blood oxygen saturation to perturbation
15 artifact;
16 placing said sensor on said fetus;
17 measuring an intensity of at least two light
18 signals from said light source at said light detector
19 after being scattered through a portion of said fetus;
20 and

21 determining said blood oxygen saturation using
22 said intensity and said pulse oximeter.

1 18. The method of claim 17 further comprising the
2 step of measuring a third light signal from detected light
3 scattered through a portion of said fetus, the third light
4 signal having a mean wavelength less than 700 nanometers and
5 being optimized for an oxygen saturation reading greater than
6 65% percent.

1 19. A method for using a pulse oximeter to measure
2 blood oxygen saturation in a patient, comprising the steps of:
3 selecting a light source and a light detector
4 for a sensor;
5 detecting light at said detector comprising
6 first and second light spectrums, each of the light
7 spectrums having an extinction and a scattering
8 coefficient associated with blood perfused tissue;
9 optimizing said light spectrums by choosing
10 wavelength spectrums whose product of their respective
11 extinction and scattering coefficients form first and
12 second values, a ratio between said first and second
13 values being between 0.5 and 2 for a majority of the
14 oxygen saturation reading range of 0 to 65 percent;
15 placing said sensor on said patient; and
16 determining said blood oxygen saturation using
17 said sensor and said pulse oximeter.

1 20. The method of claim 19 further comprising the
2 step of alternately optimizing said light spectrum for an
3 oxygen saturation reading range greater than 65% percent.

1 21. A method for measuring blood oxygen saturation
2 in a fetus, comprising the steps of:
3 providing a sensor and a pulse oximeter;
4 selecting a far red and infrared light source
5 and a light detector;

6 detecting light at said detector including an
7 infrared wavelength spectrum useful for measuring oxygen
8 saturation in a patient with high saturation, the
9 detected light including a far red wavelength spectrum
10 which has a mean wavelength between 700 and 790
11 nanometers;

12 placing said light sources in a single
13 encapsulated package and mounting said package on said
14 sensor;

15 placing said sensor on said fetus;

16 measuring an intensity of light from said light
17 source at said light detector after scattering through a
18 portion of said fetus; and

19 determining said blood oxygen saturation using
20 said intensity and said pulse oximeter.

1 22. The method of claim 21 further comprising the
2 steps of:

3 selecting a second red light source;

4 selecting a wavelength spectrum of said second
5 red light source to have a mean wavelength less than 700
6 nanometers; and

7 selectively activating either or both said
8 first mentioned or second red light source.

1 23. A fetal pulse oximeter sensor comprising:

2 a housing;

3 at least one light source mounted in said
4 housing;

5 at least one detector mounted in said housing;

6 means for detecting light subsequent to being
7 scattered by fetal tissue, the light including an
8 infrared light spectrum, said infrared spectrum having a
9 range useful for measuring oxygen saturation in a patient
10 with high saturation, the detected light also including a
11 red light spectrum, said red light spectrum having a mean
12 wavelength between 700 and 790 nanometers; and

13 said detector being mounted in said housing
14 spaced from said light sources and positioned to detect
15 light from said light sources.

1 24. The sensor of claim 23 wherein said light
2 source comprises at least one LED.

1 25. The sensor of claim 23 wherein said light
2 source comprises red and infrared light sources spaced from
3 said detector by at least 10 mm.

1 26. The sensor of claim 23 wherein said light
2 source comprises red and infrared light sources spaced from
3 said detector by at least 14 mm.

1 27. The sensor of claim 23 wherein said means for
2 providing comprises a light source which emits a limited
3 spectrum.

1 28. The sensor of claim 23 wherein said means for
2 providing comprises a filter between said light source and
3 said detector for passing a limited spectrum of light.

1 29. The sensor of claim 23 wherein said means for
2 providing comprises a wavelength sensitive detector which
3 detects a limited spectrum of light.

1 30. The sensor of claim 23 further comprising:
2 means for providing a red light spectrum having
3 a mean wavelength less than 700 nanometers.

1 31. The sensor of claim 30 wherein
2 said means for providing a red light spectrum
3 having a mean wavelength between 700 and 790 nanometers
4 is a first light emitting diode; and
5 said means for providing a red light spectrum
6 having a mean wavelength less than 700 nanometers is a
7 second light emitting diode.

1 32. A sensor for a pulse oximeter for measuring
2 blood oxygen saturation, comprising:
3 a light source;
4 a light detector;
5 one of said light source and light detector
6 including means for providing light comprising first and
7 second spectrums, each of the spectrums being optimized
8 for the products of their respective extinction and
9 scattering coefficients in blood perfused tissue, the
10 products forming first and second values, a ratio between
11 said first and second values being between 0.5 and 2 for
12 a majority of the oxygen saturations less than 80
13 percent.

1 33. The sensor of claim 32 wherein said light
2 source and said detector are spaced apart by at least 14 mm.

1 34. The sensor of claim 32 further comprising means
2 for providing a red spectrum having a mean wavelength less
3 than 700 nanometers.

1 35. A sensor for a pulse oximeter for measuring
2 blood oxygen saturation in a fetus, comprising:
3 a radiation source;
4 a radiation detector;
5 at least one of said source and detector being
6 optimized for reducing the sensitivity of a blood oxygen
7 saturation measurement to perturbation induced artifact
8 for saturations less than 65 percent.

1 36. The sensor of claim 35 wherein said radiation
2 source comprises red and infrared LEDs spaced from said
3 detector by at least 10 mm.

1 37. The sensor of claim 35 wherein said radiation
2 source comprises red and infrared LEDs spaced from said
3 detector by at least 14 mm.

1 38. The sensor of claim 35 further comprising means
2 for alternately optimizing said source and detector for oxygen
3 saturation readings greater than 65%.

1 39. The sensor of claim 38 further comprising a
2 second red light source having a mean wavelength less than 700
3 nanometers.

1 40. A sensor for measuring blood oxygen saturation
2 in a fetus, comprising:

3 an infrared light source having a wavelength
4 spectrum useful for measuring oxygen saturation in a
5 patient with high saturation;

6 a deep red light source having a mean
7 wavelength between 700 and 790 nanometers; and

8 a single encapsulated package enclosing said
9 red and infrared light sources, said package being
10 mounted on said sensor.

1 41. A method of using a pulse oximeter, comprising
2 the steps of:

3 receiving at least first and second signals
4 from a sensor obtained by scattering light through
5 tissue, the light having at least first and second
6 wavelength spectrums, the first and second spectrums
7 being optimized for an oxygen saturation reading less
8 than 80%; and

9 calculating the oxygen saturation using
10 coefficients suitable for the first and second optimized
11 spectrums.

1 42. A method for measuring blood oxygen saturation
2 in a fetus, comprising the steps of:

3 providing a sensor and a pulse oximeter;
4 selecting a light source and a far red and
5 infrared light detector;

6 detecting light at said detector including an
7 infrared light wavelength spectrum useful for measuring

8 oxygen saturation in a patient with high saturation, the
9 detected light including a far red wavelength spectrum
10 which has a mean wavelength between 700 and 790
11 nanometers;

12 placing said light detectors in a single
13 encapsulated package and mounting said package on said
14 sensor;

15 placing said sensor on said fetus;

16 measuring an intensity of light from said light
17 source at said light detectors after scattering through a
18 portion of said fetus; and

19 determining said blood oxygen saturation using
20 said intensity and said pulse oximeter.

1 43. The method of claim 42 further comprising the
2 steps of:

3 selecting said detector to detect a second red
4 light spectrum;

5 selecting a wavelength spectrum of said second
6 red light spectrum to have a mean wavelength less than
7 700 nanometers; and

8 selectively detecting either or both said first
9 mentioned or second red light spectrums.

1 44. A pulse oximeter comprising:

2 an input connector for receiving at least first
3 and second signals from a sensor obtained by scattering
4 light through tissue, the light having at least first and
5 second wavelength spectrums;

6 a memory storing coefficients suitable for said
7 first and second spectrums, the spectrums being optimized
8 for an oxygen saturation reading less than 80%; and

9 a processor, coupled to said memory and said
10 input connector, for calculating the oxygen saturation
11 using said coefficients.

1 45. The pulse oximeter of claim 44 wherein said
2 first wavelength spectrum has a mean wavelength between 700
3 and 790 nanometers.

1 46. The pulse oximeter of claim 45 further
2 comprising:
3 a detector coupled to said connector for
4 detecting a coding signal from a sensor indicative of a
5 mean wavelength between 700 and 790 nanometers for said
6 first wavelength spectrum.

1 47. The pulse oximeter of claim 46 further
2 comprising:
3 a decoder, coupled to said detector and said
4 memory, for selecting appropriate coefficients from said
5 memory based on said coding signal.

1 48. The pulse oximeter of claim 46 wherein said
2 detector further comprises means for passing a current through
3 an impedance element in said sensor, said impedance element
4 having a value indicative of a mean wavelength between 700 and
5 790 nanometers for said first wavelength spectrum.

1 49. A fetal pulse oximeter comprising:
2 an input connector for receiving at least first
3 and second signals from a sensor obtained by scattering
4 light through tissue of a fetus, the light having at
5 least red and infrared spectrums;
6 a memory storing coefficients suitable for said
7 infrared spectrum having a range useful for measuring
8 oxygen saturation in a patient with high saturation and
9 said red light spectrum having a mean wavelength between
10 700 and 790 nanometers; and
11 a processor, coupled to said memory and said
12 input connector, for calculating the oxygen saturation of
13 said fetus using said coefficients.

1 50. The pulse oximeter of claim 49 wherein said
2 memory further comprises:
3 coefficients for a red light spectrum having a
4 mean wavelength less than 700 nanometers.

1 51. A pulse oximeter, comprising:
2 an input connector for receiving at least first
3 and second signals from a sensor obtained by scattering
4 light through tissue, the light having at least red and
5 infrared spectrums;
6 a memory storing coefficients suitable for said
7 spectrums, each of the spectrums being optimized for the
8 products of their respective extinction and scattering
9 coefficients in blood perfused tissue, the products
10 forming first and second values, a ratio between said
11 first and second values being between 0.5 and 2 for a
12 majority of oxygen saturations less than 80 percent; and
13 a processor, coupled to said memory, for
14 calculating the oxygen saturation using said
15 coefficients.

1 52. A pulse oximeter for measuring blood oxygen
2 saturation in a fetus, comprising:
3 an input connector for receiving at least first
4 and second signals from a sensor obtained by detecting
5 light having at least red and infrared spectrums, the
6 light being scattered from tissue;
7 a memory storing coefficients suitable for said
8 spectrums being optimized for reducing the sensitivity of
9 a blood oxygen saturation measurement to perturbation
10 induced artifact for saturations less than 65 percent;
11 and
12 a processor, coupled to said memory, for
13 calculating the oxygen saturation using said
14 coefficients.




FIG. 1.




FIG. 2.




FIG. 3.




FIG. 4A.

EXTINCTION-SCATTERING COEFFICIENT PRODUCT (L/mmole·cm ²)	660 nm	732 nm	892 nm
$\mu's \cdot \beta_{HbO2}$	1.23	1.31	2.82
$\mu's \cdot \beta_{85\%}$	2.67	1.63	2.64
$\mu's \cdot \beta_{40\%}$	7.00	2.58	1.84
$\mu's \cdot \beta_{Hb}$	10.85	3.41	1.59

FIG. 4B.

3/14




FIG. 5.




FIG. 6.




FIG. 7A.




FIG. 7B.




FIG. 8A.




FIG. 8B.




FIG. 9A.




FIG. 9B.




FIG. 10A.




FIG. 10B.




FIG. 11A.




FIG. 11B.




FIG. 12A.




FIG. 12B.




FIG. 13A.




FIG. 13B.




FIG. 14A.




FIG. 14B.




FIG. 15A.




FIG. 15B.




FIG. 16A.




FIG. 16B.




FIG. 17A.




FIG. 17B.

7/14




FIG. 18A.




FIG. 18B.




FIG. 24.




FIG. 25.

8/14




FIG. 19.

9/14




FIG. 20.

10/14




FIG. 21.

11/14




FIG. 22.

12/14




FIG. 23.




FIG. 26A.




FIG. 26B.




FIG. 27.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/04050

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61B5/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61B

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X A A	EP-A-0 522 674 (M. R. ROBINSON) 13 January 1993 see page 9, line 46 - line 53 see page 12, line 15 - page 13, line 47 see page 16, line 33 - page 17, line 14; claims; figure 1 --- PEDIATRIC RESEARCH, vol. 31, no. 3, 1992 BALTIMORE (US), pages 266-269, XP 000444521 A. CARIN DASSEL 'Reflectance Pulse Oximetry in Fetal Lambs' see abstract see Section "Materials and Method" --- -/--	35,41, 44,49,52 1,17,21, 23,32, 42,51 1,2,17, 23,35, 41-43, 49,51,52

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

18 July 1995

Date of mailing of the international search report

27. 07. 95

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+ 31-70) 340-3016

Authorized officer

 Fontenay, P

INTERNATIONAL SEARCH REPORT

Intern: 1 Application No
PCT/US 95/04050

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>WO-A-92 21283 (SOMANETICS CORPORATION) 10 December 1992</p> <p style="margin-left: 40px;">see page 11, line 4 - page 12, line 7 -----</p>	<p>1,9,10, 17,19, 21,23, 31, 40-42, 44,45, 48,49</p>

1

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/04050

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-522674	13-01-93	JP-A- 5261088	12-10-93
WO-A-9221283	10-12-92	CA-A- 2110716	10-12-92
		EP-A- 0597875	25-05-94
		JP-T- 7500259	12-01-95